Screener
Avalo Therapeutics AVTX Maryland — Increase (Decrease) in Right Of Use Asset
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:IncreaseDecreaseInRightOfUseAsset.
The source filing: Avalo Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 7:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000033
FAQ
- What is Avalo Therapeutics's maryland — increase (decrease) in right of use asset?
- Avalo Therapeutics (AVTX) reported maryland — increase (decrease) in right of use asset of -$300K in Q1 2026.
- How has Avalo Therapeutics's maryland — increase (decrease) in right of use asset changed year-over-year?
- Avalo Therapeutics's maryland — increase (decrease) in right of use asset decreased by 0.0% year-over-year, from -$300K to -$300K.
- What does maryland — increase (decrease) in right of use asset mean?
- The net change in the carrying value of the right-of-use asset recognized on the balance sheet for operating leases in the Maryland segment. This metric tracks the valuation of the company's right to use leased property, adjusted for amortization, impairments, or new lease acquisitions.
Ask your AI about Avalo Therapeutics's maryland — increase (decrease) in right of use asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude